Arcutis Biotherapeutics Inc (ARQT)

$20.05 -0.66 (-3.19%)
Market Cap 2.48B
Revenue (ttm) 196.54M
Net Income (ttm) -140.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -71.25%
Debt to Equity Ratio 0.78
Volume 1,824,600
Avg Vol 1,881,106
Day's Range N/A - N/A
Shares Out 119.91M
Stochastic %K 49%
Beta 2.06
Analysts Strong Sell
Price Target $23.38

Company Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK...

Industry: Biotechnology
Sector: Healthcare
Phone: 805 418 5006
Address:
3027 Townsgate Road, Suite 300, Westlake Village, United States
eal163
eal163 Oct. 11 at 5:32 PM
$ARQT https://youtu.be/kZY-8GYPok4?si=klWLCcEodISPEnQG smart CEO
0 · Reply
BOXLinvestor
BOXLinvestor Oct. 10 at 5:35 PM
$ARQT Arcutis Biotherapeutics (option volume 10-10-25) 20.04 -3.2% | 61 trades | total $114.3 K | 90-day avg $89.7 K × 1.27 call $114 K | put $270 | 56% single-leg, 44% multi-leg
0 · Reply
Rhody27
Rhody27 Oct. 10 at 2:38 PM
$ARQT bring it down shorts, so I can add again.
0 · Reply
liadanielle
liadanielle Oct. 9 at 3:04 PM
$ARQT  in a year it’s possible for this to be a $50 stock
1 · Reply
liadanielle
liadanielle Oct. 9 at 3:03 PM
$ARQT it’s so great to say I’m buying this dip at $20 and change ha ha ha great company I love this
0 · Reply
BOXLinvestor
BOXLinvestor Oct. 9 at 11:59 AM
$ARQT Arcutis Biotherapeutics (option volume 10-08-25) 21.24 +3.3% | 306 trades | total $446.9 K | 90-day avg $86 K × 5.20 call $443.6 K | put $3.3 K | 57% single-leg, 43% multi-leg
0 · Reply
BOXLinvestor
BOXLinvestor Oct. 9 at 8:18 AM
$ARQT Arcutis Biotherapeutics (option volume 10-08-25) 21.24 +3.3% | 306 trades | total $446.9 K | 90-day avg $86 K × 5.20 call $443.6 K | put $3.3 K | 57% single-leg, 43% multi-leg
0 · Reply
zawojak
zawojak Oct. 8 at 6:30 PM
$ARQT I may be wrong again buy I can smell BO guys !!!
1 · Reply
Chasetae
Chasetae Oct. 8 at 6:03 PM
$ARQT haven't seen .02 spreads here in a long time! Shorty best get to buying.
0 · Reply
UpsidePotential22
UpsidePotential22 Oct. 8 at 5:55 PM
$ARQT ARCUTIS BIOTHERAPEUTICS (NASDAQ: ARQT): TIME TO HAVE SKIN IN THIS GAME! Excited to share an article about Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company creating a portfolio of targeted therapies to treat immune-mediated dermatological diseases and conditions. On October 6, 2025, the U.S. Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for ZORYVE® (roflumilast) cream 0.05% intended for the treatment of mild to moderate atopic dermatitis in children aged 2 to 5. The approval of ZORYVE cream 0.05% will be a new topical therapy option that can address the unmet needs of over 1.8 million children aged 2 to 5 with atopic dermatitis (AD) in the United States. Read on to find out more! https://www.aviseanalytics.com/arcutis-biotherapeutics-nasdaq-arqt-time-to-have-skin-in-this-game/
0 · Reply
Latest News on ARQT
FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

Oct 6, 2025, 8:00 AM EDT - 5 days ago

FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 3, 2025, 4:00 PM EDT - 7 days ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025

Sep 29, 2025, 4:00 PM EDT - 11 days ago

Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress

Sep 17, 2025, 4:00 AM EDT - 24 days ago

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress

Allure Magazine Honors Arcutis' ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award

Sep 16, 2025, 9:00 AM EDT - 25 days ago

Allure Magazine Honors Arcutis' ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award

Arcutis Biotherapeutics, Inc. (ARQT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 6:37 PM EDT - 4 weeks ago

Arcutis Biotherapeutics, Inc. (ARQT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Arcutis Biotherapeutics, Inc. (ARQT) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 3:08 PM EDT - 5 weeks ago

Arcutis Biotherapeutics, Inc. (ARQT) Presents At Citi's Biopharma Back To School Conference Transcript

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

Sep 3, 2025, 11:43 AM EDT - 5 weeks ago

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

Arcutis: ZORYVE's Multi-Indication Momentum And Margin Expansion Justify A Bullish Re-Rate

Aug 23, 2025, 3:37 AM EDT - 7 weeks ago

Arcutis: ZORYVE's Multi-Indication Momentum And Margin Expansion Justify A Bullish Re-Rate

Arcutis to Present at Upcoming Investor Conferences

Aug 19, 2025, 4:00 PM EDT - 7 weeks ago

Arcutis to Present at Upcoming Investor Conferences

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 2:53 AM EDT - 2 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2025 Earnings Call Transcript

Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:00 PM EDT - 2 months ago

Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update

Arcutis: Leveraging Zoryve's Success While Positioning For Pipeline Expansion

Aug 1, 2025, 3:54 PM EDT - 2 months ago

Arcutis: Leveraging Zoryve's Success While Positioning For Pipeline Expansion

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

Jul 23, 2025, 4:00 PM EDT - 2 months ago

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction

Jun 27, 2025, 11:25 PM EDT - 3 months ago

Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction

Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

Jun 26, 2025, 8:00 AM EDT - 3 months ago

Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

Arcutis Biotherapeutics: Another Approval Under Their Belt

Jun 25, 2025, 4:43 AM EDT - 3 months ago

Arcutis Biotherapeutics: Another Approval Under Their Belt

Arcutis: Out Of The Woods, Ready For Commercialization

Jun 12, 2025, 11:57 PM EDT - 4 months ago

Arcutis: Out Of The Woods, Ready For Commercialization

Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

Jun 10, 2025, 8:00 AM EDT - 4 months ago

Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

Jun 6, 2025, 8:00 AM EDT - 4 months ago

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

Arcutis Biotherapeutics: Navigating Commercialization With Promising Upside

Jun 5, 2025, 1:07 AM EDT - 4 months ago

Arcutis Biotherapeutics: Navigating Commercialization With Promising Upside

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

May 29, 2025, 4:00 PM EDT - 4 months ago

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

May 22, 2025, 2:12 PM EDT - 5 months ago

Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice

May 15, 2025, 9:29 AM EDT - 5 months ago

New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

May 7, 2025, 11:18 AM EDT - 5 months ago

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

Arcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:00 PM EDT - 5 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call Transcript

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 4:00 PM EDT - 5 months ago

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets

Apr 19, 2025, 1:41 AM EDT - 6 months ago

Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

Apr 17, 2025, 8:00 AM EDT - 6 months ago

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

Arcutis Announces Chief Financial Officer Transition

Apr 10, 2025, 4:30 PM EDT - 6 months ago

Arcutis Announces Chief Financial Officer Transition

Arcutis and Padagis Agree to Stay Patent Lawsuit

Apr 2, 2025, 1:16 PM EDT - 6 months ago

Arcutis and Padagis Agree to Stay Patent Lawsuit

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 8:00 AM EDT - 7 months ago

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

Mar 25, 2025, 8:16 AM EDT - 7 months ago

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

TNXP

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

Mar 7, 2025, 8:00 AM EST - 7 months ago

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

Feb 28, 2025, 9:00 AM EST - 8 months ago

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

Arcutis: ZORYVE Net Product Revenue Growth Isn't The Only Opportunity On Deck

Feb 27, 2025, 6:17 AM EST - 8 months ago

Arcutis: ZORYVE Net Product Revenue Growth Isn't The Only Opportunity On Deck

Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations

Feb 26, 2025, 2:28 PM EST - 8 months ago

Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations

U.S. FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Feb 26, 2025, 8:00 AM EST - 8 months ago

U.S. FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis Biotherapeutics, Inc. (ARQT) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 10:53 PM EST - 8 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Q4 2024 Earnings Call Transcript

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 25, 2025, 4:00 PM EST - 8 months ago

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology

Feb 24, 2025, 8:00 AM EST - 8 months ago

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology

Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 4:35 PM EST - 8 months ago

Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"

Feb 4, 2025, 9:15 AM EST - 8 months ago

Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

Jan 12, 2025, 8:30 AM EST - 9 months ago

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?

Nov 15, 2024, 8:30 AM EST - 11 months ago

Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?

Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 2:24 AM EST - 1 year ago

Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 4:00 PM EST - 1 year ago

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

Oct 23, 2024, 4:00 PM EDT - 1 year ago

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4

Oct 22, 2024, 7:36 AM EDT - 1 year ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4

OGN TMDX

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

Oct 18, 2024, 8:20 AM EDT - 1 year ago

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

eal163
eal163 Oct. 11 at 5:32 PM
$ARQT https://youtu.be/kZY-8GYPok4?si=klWLCcEodISPEnQG smart CEO
0 · Reply
BOXLinvestor
BOXLinvestor Oct. 10 at 5:35 PM
$ARQT Arcutis Biotherapeutics (option volume 10-10-25) 20.04 -3.2% | 61 trades | total $114.3 K | 90-day avg $89.7 K × 1.27 call $114 K | put $270 | 56% single-leg, 44% multi-leg
0 · Reply
Rhody27
Rhody27 Oct. 10 at 2:38 PM
$ARQT bring it down shorts, so I can add again.
0 · Reply
liadanielle
liadanielle Oct. 9 at 3:04 PM
$ARQT  in a year it’s possible for this to be a $50 stock
1 · Reply
liadanielle
liadanielle Oct. 9 at 3:03 PM
$ARQT it’s so great to say I’m buying this dip at $20 and change ha ha ha great company I love this
0 · Reply
BOXLinvestor
BOXLinvestor Oct. 9 at 11:59 AM
$ARQT Arcutis Biotherapeutics (option volume 10-08-25) 21.24 +3.3% | 306 trades | total $446.9 K | 90-day avg $86 K × 5.20 call $443.6 K | put $3.3 K | 57% single-leg, 43% multi-leg
0 · Reply
BOXLinvestor
BOXLinvestor Oct. 9 at 8:18 AM
$ARQT Arcutis Biotherapeutics (option volume 10-08-25) 21.24 +3.3% | 306 trades | total $446.9 K | 90-day avg $86 K × 5.20 call $443.6 K | put $3.3 K | 57% single-leg, 43% multi-leg
0 · Reply
zawojak
zawojak Oct. 8 at 6:30 PM
$ARQT I may be wrong again buy I can smell BO guys !!!
1 · Reply
Chasetae
Chasetae Oct. 8 at 6:03 PM
$ARQT haven't seen .02 spreads here in a long time! Shorty best get to buying.
0 · Reply
UpsidePotential22
UpsidePotential22 Oct. 8 at 5:55 PM
$ARQT ARCUTIS BIOTHERAPEUTICS (NASDAQ: ARQT): TIME TO HAVE SKIN IN THIS GAME! Excited to share an article about Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company creating a portfolio of targeted therapies to treat immune-mediated dermatological diseases and conditions. On October 6, 2025, the U.S. Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for ZORYVE® (roflumilast) cream 0.05% intended for the treatment of mild to moderate atopic dermatitis in children aged 2 to 5. The approval of ZORYVE cream 0.05% will be a new topical therapy option that can address the unmet needs of over 1.8 million children aged 2 to 5 with atopic dermatitis (AD) in the United States. Read on to find out more! https://www.aviseanalytics.com/arcutis-biotherapeutics-nasdaq-arqt-time-to-have-skin-in-this-game/
0 · Reply
eal163
eal163 Oct. 8 at 5:39 PM
$ARQT $MRK i could see this being acquired
1 · Reply
Artster25
Artster25 Oct. 8 at 4:43 PM
$ARQT short interest 13% as of Sept. 15th according to Fintel ! 9 days to cover. Rocket fuel as they cover
0 · Reply
ChessGM
ChessGM Oct. 8 at 2:42 PM
$ARQT This is just a start. Estimated 3X profitability next year will have a positive impact on stock price. https://www.youtube.com/watch?v=fOu4gh4WaNM
0 · Reply
Chasetae
Chasetae Oct. 8 at 2:34 PM
$ARQT new 52 Week high.
0 · Reply
ChessGM
ChessGM Oct. 7 at 7:19 PM
$ARQT Showing some strength
0 · Reply
liadanielle
liadanielle Oct. 7 at 7:18 PM
$ARQT come on baby break 21
0 · Reply
JazzyJ03
JazzyJ03 Oct. 7 at 6:56 PM
$ARQT
0 · Reply
JazzyJ03
JazzyJ03 Oct. 7 at 6:41 PM
$ARQT long!
0 · Reply
Bornjever
Bornjever Oct. 7 at 6:05 PM
$ARQT you all do realize the PDUFA already got approved last week . Now we are waiting for the earn at the end of the month. I know I have missed and early PDUFA sometimes because news is not necessarily shared as much and we are all very busy for this crazy world we live in. The price should be dropping like it should after a PDUFA
1 · Reply
liadanielle
liadanielle Oct. 7 at 5:59 PM
$ARQT Holding long. Very bullish. Although the product is extremely expensive it will still bear fruit. Insurance companies normally pick up on products that work so they don’t have to pay long-term residuals. And hopefully they can get the cost down somehow.
1 · Reply
lakeswim951
lakeswim951 Oct. 7 at 4:42 PM
$ARQT Just a textbook bounce off 8 day ema with a hammer.
0 · Reply
liadanielle
liadanielle Oct. 7 at 4:13 PM
$ARQT When my daughter was a baby, she had a horrible skin condition on her backside and legs! Went to several doctors went as far as to drove out of state to a specific pharmacist to have something made by hand in a pharmacy. Just spoke to my dermatologist this is the greatest product ever made. He gave me a bunch of samples to use on a small condition I have and it’s incredible.
1 · Reply